Michael J. LaBarre - Apr 16, 2024 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
SVP, CHIEF TECHNICAL OFFICER
Signature
/s/ James R. Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Apr 16, 2024
Transactions value $
-$606,190
Form type
4
Date filed
4/17/2024, 07:22 PM
Previous filing
Mar 26, 2024
Next filing
May 22, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $81.1K +10K +5.95% $8.11 178K Apr 16, 2024 Direct F1
transaction HALO Common Stock Sale -$384K -10K -5.61% $38.35 168K Apr 16, 2024 Direct F1
transaction HALO Common Stock Options Exercise $81.1K +10K +5.95% $8.11 178K Apr 17, 2024 Direct F1
transaction HALO Common Stock Sale -$385K -10K -5.61% $38.49 168K Apr 17, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Options Exercise $0 -10K -16.2% $0.00 51.7K Apr 16, 2024 Common Stock 10K $8.11 Direct F1, F3
transaction HALO Option to Purchase Common Stock Options Exercise $0 -10K -19.34% $0.00 41.7K Apr 17, 2024 Common Stock 10K $8.11 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 9, 2023.
F2 Represents a weighted average sales price per share. These shares were sold at prices ranging from $38.275 to $38.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 This option was granted on February 3, 2016 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.